VTGN Annual EBITDA
-$32.45 M
+$26.28 M+44.75%
31 March 2024
Summary:
As of January 19, 2025, VTGN annual earnings before interest, taxes, depreciation & amortization is -$32.45 million, with the most recent change of +$26.28 million (+44.75%) on March 31, 2024. During the last 3 years, it has fallen by -$15.01 million (-86.07%). VTGN annual EBITDA is now -381700.00% below its all-time high of -$8500.00, reached on December 31, 2010.VTGN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VTGN Quarterly EBITDA
-$14.07 M
-$2.09 M-17.45%
30 September 2024
Summary:
As of January 19, 2025, VTGN quarterly earnings before interest, taxes, depreciation & amortization is -$14.07 million, with the most recent change of -$2.09 million (-17.45%) on September 30, 2024. Over the past year, it has dropped by -$2.86 million (-25.48%). VTGN quarterly EBITDA is now -2752.71% below its all-time high of $530.40 thousand, reached on December 31, 2013.VTGN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VTGN TTM EBITDA
-$45.00 M
-$7.43 M-19.77%
30 September 2024
Summary:
As of January 19, 2025, VTGN TTM earnings before interest, taxes, depreciation & amortization is -$45.00 million, with the most recent change of -$7.43 million (-19.77%) on September 30, 2024. Over the past year, it has dropped by -$12.55 million (-38.67%). VTGN TTM EBITDA is now -2045513.64% below its all-time high of -$2200.00, reached on March 31, 2007.VTGN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VTGN EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +44.8% | -25.5% | -38.7% |
| 3 y3 years | -86.1% | -105.1% | +2.1% |
| 5 y5 years | -32.5% | -334.8% | -117.9% |
VTGN EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -86.1% | +44.8% | -111.9% | +28.4% | -38.7% | +29.4% |
| 5 y | 5-year | -86.1% | +44.8% | -355.4% | +28.4% | -208.2% | +29.4% |
| alltime | all time | <-9999.0% | +44.8% | -2752.7% | +67.7% | <-9999.0% | +44.8% |
VistaGen Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$14.07 M(+17.4%) | -$45.00 M(+19.8%) |
| June 2024 | - | -$11.98 M(+6.8%) | -$37.57 M(+15.8%) |
| Mar 2024 | -$32.45 M(-44.7%) | -$11.21 M(+44.9%) | -$32.45 M(-2.7%) |
| Dec 2023 | - | -$7.74 M(+16.6%) | -$33.34 M(-5.4%) |
| Sept 2023 | - | -$6.64 M(-3.2%) | -$35.24 M(-23.3%) |
| June 2023 | - | -$6.86 M(-43.3%) | -$45.95 M(-21.8%) |
| Mar 2023 | -$58.74 M(+24.8%) | -$12.10 M(+25.6%) | -$58.73 M(-7.0%) |
| Dec 2022 | - | -$9.63 M(-44.5%) | -$63.18 M(-0.9%) |
| Sept 2022 | - | -$17.36 M(-11.6%) | -$63.77 M(+7.9%) |
| June 2022 | - | -$19.64 M(+18.6%) | -$59.07 M(+25.6%) |
| Mar 2022 | -$47.05 M(+169.8%) | -$16.55 M(+62.0%) | -$47.05 M(+28.7%) |
| Dec 2021 | - | -$10.22 M(-19.3%) | -$36.57 M(+16.0%) |
| Sept 2021 | - | -$12.66 M(+66.3%) | -$31.53 M(+43.6%) |
| June 2021 | - | -$7.61 M(+25.3%) | -$21.96 M(+25.9%) |
| Mar 2021 | -$17.44 M(-15.6%) | -$6.08 M(+17.4%) | -$17.44 M(+19.5%) |
| Dec 2020 | - | -$5.18 M(+67.6%) | -$14.60 M(-4.9%) |
| Sept 2020 | - | -$3.09 M(-0.2%) | -$15.36 M(-12.6%) |
| June 2020 | - | -$3.10 M(-4.3%) | -$17.57 M(-14.9%) |
| Mar 2020 | -$20.65 M(-15.7%) | -$3.24 M(-45.5%) | -$20.65 M(-10.6%) |
| Dec 2019 | - | -$5.93 M(+11.8%) | -$23.11 M(-5.1%) |
| Sept 2019 | - | -$5.31 M(-14.1%) | -$24.37 M(-7.9%) |
| June 2019 | - | -$6.18 M(+8.5%) | -$26.47 M(+8.1%) |
| Mar 2019 | -$24.49 M(+77.1%) | -$5.70 M(-20.8%) | -$24.49 M(+1.3%) |
| Dec 2018 | - | -$7.19 M(-3.0%) | -$24.18 M(+23.6%) |
| Sept 2018 | - | -$7.41 M(+76.6%) | -$19.56 M(+16.1%) |
| June 2018 | - | -$4.19 M(-22.1%) | -$16.84 M(+13.1%) |
| Mar 2018 | -$13.83 M(+41.6%) | -$5.39 M(+109.5%) | -$14.88 M(+23.7%) |
| Dec 2017 | - | -$2.57 M(-45.2%) | -$12.03 M(+2.7%) |
| Sept 2017 | - | -$4.69 M(+109.6%) | -$11.71 M(+16.1%) |
| June 2017 | - | -$2.24 M(-11.6%) | -$10.09 M(+3.4%) |
| Mar 2017 | -$9.77 M(-78.9%) | -$2.53 M(+12.2%) | -$9.77 M(-80.8%) |
| Dec 2016 | - | -$2.26 M(-26.5%) | -$50.82 M(+0.2%) |
| Sept 2016 | - | -$3.07 M(+60.7%) | -$50.70 M(-7.2%) |
| June 2016 | - | -$1.91 M(-95.6%) | -$54.64 M(-33.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | -$46.39 M(+403.8%) | -$43.59 M(+1944.7%) | -$81.49 M(+95.4%) |
| Dec 2015 | - | -$2.13 M(-69.6%) | -$41.69 M(+4.7%) |
| Sept 2015 | - | -$7.01 M(-75.6%) | -$39.83 M(+16.5%) |
| June 2015 | - | -$28.76 M(+658.0%) | -$34.20 M(+271.4%) |
| Mar 2015 | -$9.21 M(+582.8%) | -$3.79 M(+1341.1%) | -$9.21 M(+37.4%) |
| Dec 2014 | - | -$263.30 K(-80.9%) | -$6.70 M(+13.4%) |
| Sept 2014 | - | -$1.38 M(-63.4%) | -$5.91 M(+5.1%) |
| June 2014 | - | -$3.77 M(+193.1%) | -$5.62 M(+317.0%) |
| Mar 2014 | -$1.35 M(-88.6%) | -$1.29 M(-342.5%) | -$1.35 M(-61.1%) |
| Dec 2013 | - | $530.40 K(-148.5%) | -$3.46 M(-61.5%) |
| Sept 2013 | - | -$1.09 M(-317.9%) | -$9.00 M(-6.3%) |
| June 2013 | - | $501.60 K(-114.7%) | -$9.61 M(-18.4%) |
| Mar 2013 | -$11.85 M(+15.4%) | -$3.40 M(-32.1%) | -$11.78 M(-9.8%) |
| Dec 2012 | - | -$5.01 M(+194.3%) | -$13.06 M(+8.1%) |
| Sept 2012 | - | -$1.70 M(+2.6%) | -$12.08 M(-0.8%) |
| June 2012 | - | -$1.66 M(-64.6%) | -$12.17 M(-0.1%) |
| Mar 2012 | -$10.27 M(>+9900.0%) | -$4.69 M(+16.2%) | -$12.18 M(+62.4%) |
| Dec 2011 | - | -$4.03 M(+124.6%) | -$7.50 M(+116.2%) |
| Sept 2011 | - | -$1.80 M(+7.7%) | -$3.47 M(+107.0%) |
| June 2011 | - | -$1.67 M(>+9900.0%) | -$1.68 M(>+9900.0%) |
| Mar 2011 | - | -$5200.00(+188.9%) | -$11.00 K(+29.4%) |
| Dec 2010 | -$8500.00(-60.5%) | -$1800.00(-10.0%) | -$8500.00(+6.3%) |
| Sept 2010 | - | -$2000.00(0.0%) | -$8000.00(+11.1%) |
| June 2010 | - | -$2000.00(-25.9%) | -$7200.00(0.0%) |
| Mar 2010 | - | -$2700.00(+107.7%) | -$7200.00(-66.7%) |
| Dec 2009 | -$21.50 K(+31.9%) | -$1300.00(+8.3%) | -$21.60 K(-34.9%) |
| Sept 2009 | - | -$1200.00(-40.0%) | -$33.20 K(+3.4%) |
| June 2009 | - | -$2000.00(-88.3%) | -$32.10 K(+2.9%) |
| Mar 2009 | - | -$17.10 K(+32.6%) | -$31.20 K(+91.4%) |
| Dec 2008 | -$16.30 K | -$12.90 K(>+9900.0%) | -$16.30 K(+379.4%) |
| Sept 2008 | - | -$100.00(-90.9%) | -$3400.00(+3.0%) |
| June 2008 | - | -$1100.00(-50.0%) | -$3300.00(-26.7%) |
| Mar 2008 | - | -$2200.00(-4.3%) | -$4500.00(0.0%) |
| June 2007 | - | -$2300.00(+4.5%) | -$4500.00(+104.5%) |
| Mar 2007 | - | -$2200.00 | -$2200.00 |
FAQ
- What is VistaGen Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual EBITDA year-on-year change?
- What is VistaGen Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly EBITDA year-on-year change?
- What is VistaGen Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for VistaGen Therapeutics?
- What is VistaGen Therapeutics TTM EBITDA year-on-year change?
What is VistaGen Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of VTGN is -$32.45 M
What is the all time high annual EBITDA for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$8500.00
What is VistaGen Therapeutics annual EBITDA year-on-year change?
Over the past year, VTGN annual earnings before interest, taxes, depreciation & amortization has changed by +$26.28 M (+44.75%)
What is VistaGen Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of VTGN is -$14.07 M
What is the all time high quarterly EBITDA for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $530.40 K
What is VistaGen Therapeutics quarterly EBITDA year-on-year change?
Over the past year, VTGN quarterly earnings before interest, taxes, depreciation & amortization has changed by -$2.86 M (-25.48%)
What is VistaGen Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of VTGN is -$45.00 M
What is the all time high TTM EBITDA for VistaGen Therapeutics?
VistaGen Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2200.00
What is VistaGen Therapeutics TTM EBITDA year-on-year change?
Over the past year, VTGN TTM earnings before interest, taxes, depreciation & amortization has changed by -$12.55 M (-38.67%)